Additionally, the downregulation of SOX17 by the pathological estrogen metabolite 16α‐hydroxyestrone may contribute to PAH development, linking sexual dimorphism and SOX17 genetics in PAH [75, 76]. Here, SOX17 is linked to pulmonary arterial hypertension.